Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cencora, Inc. (NYSE: COR) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large pharmaceutical solutions and distribution organization, Cencora uses its SEC reports to present detailed information about its financial performance, capital structure, governance, and significant transactions.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand Cencora’s revenue composition, segment performance for U.S. Healthcare Solutions and International Healthcare Solutions, and the impact of acquisitions such as Retina Consultants of America. These filings also describe non-GAAP measures like adjusted operating income and adjusted diluted earnings per share, along with reconciliations to GAAP metrics.
Cencora’s Form 8-K current reports offer timely updates on material events, including amendments to credit facilities, changes to its receivables securitization program, issuance and listing of senior notes, revisions to its reporting structure, and agreements to acquire additional equity interests in OneOncology. Other 8-Ks disclose governance developments, such as board appointments and leadership changes, as well as information about legal settlements and derivative actions.
Through Stock Titan, users can also track registered debt securities like Cencora’s 2.875% Senior Notes due 2028 (COR28) and 3.625% Senior Notes due 2032 (COR32), which are listed alongside the common stock. Where available, insider transaction reports on Forms 3, 4, and 5 can help users monitor equity ownership changes by directors and officers.
AI-powered tools on the platform summarize lengthy Cencora filings, highlight key changes from prior periods, and surface important disclosures about liquidity, financing arrangements, segment realignments, and legal matters. This helps readers quickly interpret complex documents and focus on the sections most relevant to their analysis of COR.
Krikorian Lazarus reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. reported that SVP & Chief Accounting Officer Lazarus Krikorian received a grant of 3,936 Restricted Stock Units on April 1, 2026. According to the filing, these Restricted Stock Units were received for no consideration and vest in full on April 1, 2028. Following this grant, Krikorian holds a total of 3,936 Restricted Stock Units directly.
The Vanguard Group filed Amendment No. 20 to a Schedule 13G/A reporting its position in Cencora Inc common stock. The filing states an amount beneficially owned: 0 shares representing 0% of the class. The amendment explains an internal realignment on January 12, 2026 that caused certain Vanguard subsidiaries and business divisions to report separately in reliance on SEC Release No. 34-39538.
Cencora, Inc. has signed a definitive agreement to acquire EyeSouth Partners’ retina business for $1.1 billion, expanding its Retina Consultants of America network. The affiliated retina physicians are expected to join RCA, strengthening Cencora’s position in specialized eye care.
Cencora expects the deal to be slightly accretive to adjusted diluted EPS in the first 12 months after closing, net of financing costs. The transaction is subject to customary closing conditions and required regulatory approvals. Cencora reaffirmed its fiscal 2026 financial guidance, which currently does not assume the transaction will close within that fiscal year.
Cencora, Inc. has announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer, effective June 30, 2026. He will assist with the search for a successor and continue in an advisory capacity through the end of 2026 to support a smooth leadership transition.
Cleary, age 62, has served as Cencora’s CFO since November 2018 and previously led MWI Veterinary Supply as CEO for over a decade before joining Cencora in 2015. The company stated that his retirement is not related to any disagreement over operations, policies, or practices.
Alongside the leadership news, Cencora reaffirmed its previously issued adjusted diluted EPS guidance for fiscal year 2026, maintaining a range of $17.45 to $17.75. Cencora highlights its scale as a global pharmaceutical solutions organization with more than $300 billion in annual revenue and over 51,000 team members worldwide.
Cencora, Inc. Executive Vice President Silvana Battaglia exercised restricted stock units into 8,415 shares of Common Stock on March 11, 2026. A portion of these shares, 3,673, was withheld at $350.30 per share to cover tax obligations related to the vesting. After these transactions, Battaglia directly owns 23,565.808 Cencora common shares.
Cencora, Inc. Executive Vice President Elizabeth S. Campbell exercised restricted stock units into common shares and had shares withheld to cover taxes. She converted 12,623 restricted stock units into 12,623 shares of common stock at no cash exercise price, then 5,842 shares were withheld at $350.30 per share to satisfy tax obligations incident to the vesting. After these compensation‑related transactions, she holds 30,705.667 shares of common stock directly.
Cencora, Inc. Chief Financial Officer James F. Cleary exercised restricted stock units into 12,623 shares of common stock. On the same date, 5,409 shares of common stock valued at $350.30 per share were withheld to satisfy tax obligations related to the vesting. After these transactions, Cleary directly owned 160,357.3479 shares of Cencora common stock.
Cooper Ellen reported acquisition or exercise transactions in this Form 4 filing.
Cencora, Inc. disclosed that director Ellen Cooper received equity awards in the form of restricted stock units. On March 5, 2026, she was granted 557 units at a reference price of $359.28 per share, increasing her direct holdings to 697 common shares. On January 30, 2026, she also received two smaller grants of 69 and 66 units at $359.22 per share, bringing her holdings to 74 and then 140 shares after those awards. Footnotes state these restricted stock unit grants were received for no cash consideration, generally vest 100% on the first anniversary of the grant date, and delivery of the underlying shares is deferred until she ceases Board service. One January grant was received in lieu of a quarterly cash retainer under the company’s non-employee director compensation program.
Cencora, Inc. director Dennis M. Nally reported acquiring a total of 655 shares of common stock in two non‑open‑market grants. On March 5, 2026, he received 557 shares at a reference price of $359.28 per share, and on January 30, 2026 he received 98 shares at $359.22 per share.
According to the footnotes, some of these shares were issued in lieu of a $35,000 quarterly cash retainer under the company’s non‑employee director compensation program, and an annual restricted stock unit grant was received for no consideration that vests 100% on the first anniversary of the grant date. After these awards, he directly owns 12,959 common shares.
Cencora, Inc. director Lauren M. Tyler reported two equity awards of common stock-based units. On March 5, 2026, Tyler acquired 557 shares as restricted stock units granted in lieu of a $30,000 quarterly cash retainer, with receipt of shares deferred until service ends. On January 30, 2026, Tyler acquired an additional 84 shares as an annual restricted stock unit grant received for no cash consideration, which vests in full on the first anniversary of the grant date. Both holdings are reported as directly owned.